Abstract
Hair cells are specialized sensory epithelia cells that receive mechanical sound waves and convert them into neural signals for hearing, and these cells can be killed or damaged by ototoxic drugs, including many aminoglycoside antibiotics, platinum-based anticancer agents, and loop diuretics, leading to drug-induced hearing loss. Studies of therapeutic approaches to drug-induced hearing loss have been hampered by the limited understanding of the biological mechanisms that protect and regenerate hair cells. This review briefly discusses some of the most common ototoxic drugs and describes recent research concerning the mechanisms of ototoxic drug-induced hearing loss. It also highlights current developments in potential therapies and explores current clinical treatments for patients with hearing impairments.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Collaborators., G.D.a.I.I.a.P (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388(10053):1545–1602
Wargo KA, Edwards JD (2014) Aminoglycoside-induced nephrotoxicity. J Pharm Pract 27(6):573–577
Ding D, Allman BL, Salvi R (2012) Review: ototoxic characteristics of platinum antitumor drugs. Anat Rec (Hoboken) 295(11):1851–1867
Forge A et al (1993) Ultrastructural evidence for hair cell regeneration in the mammalian inner ear. Science 259(5101):1616–1619
Juhn SK, Rybak LP, Prado S (1981) Nature of blood-labyrinth barrier in experimental conditions. Ann Otol Rhinol Laryngol 90(2 Pt 1):135–141
Salt AN, Plontke SK (2005) Local inner-ear drug delivery and pharmacokinetics. Drug Discov Today 10(19):1299–1306
Henley CM et al (1996) Sensitive developmental periods for kanamycin ototoxic effects on distortion-product otoacoustic emissions. Hear Res 98(1–2):93–103
Sun S et al (2014) In vivo overexpression of X-linked inhibitor of apoptosis protein protects against neomycin-induced hair cell loss in the apical turn of the cochlea during the ototoxic-sensitive period. Front Cell Neurosci 8:248
Crundwell G, Gomersall P, Baguley DM (2016) Ototoxicity (cochleotoxicity) classifications: a review. Int J Audiol 55(2):65–74
Beaubien AR et al (2009) Delay in hearing loss following drug administration. Acta Otolaryngol 109(5–6):345–352
Higashi K (1989) Unique inheritance of streptomycin-induced deafness. Clin Genet 35(6):433–436
Hu DN et al (1991) Genetic aspects of antibiotic induced deafness: mitochondrial inheritance. J Med Genet 28(2):79–83
Taylor RW, Turnbull DM (2005) Mitochondrial DNA mutations in human disease. Nat Rev Genet 6(5):389–402
Anderson S et al (1981) Sequence and organization of the human mitochondrial genome. Nature 290(5806):457–465
Prezant TR et al (1993) Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 4(3):289–294
Hamasaki K, Rando RR (1997) Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. Biochemistry 36(40):12323–12328
Xing G, Chen Z, Cao X (2007) Mitochondrial rRNA and tRNA and hearing function. Cell Res 17(3):227–239
Hobbie SN et al (2008) Genetic analysis of interactions with eukaryotic rRNA identify the mitoribosome as target in aminoglycoside ototoxicity. Proc Natl Acad Sci U S A 105(52):20888–20893
Zhao H et al (2004) Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial 12S rRNA gene in a large Chinese family. Am J Hum Genet 74(1):139–152
Zhao H et al (2005) Functional characterization of the mitochondrial 12S rRNA C1494T mutation associated with aminoglycoside-induced and non-syndromic hearing loss. Nucleic Acids Res 33(3):1132–1139
Ross CJ et al (2009) Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 41(12):1345–1349
Yang JJ et al (2013) The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther 94(2):252–259
Xu H et al (2015) Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet 47(3):263–266
Brown AL et al (2015) SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma. Cancer Med 4(11):1679–1686
Oldenburg J et al (2007) Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol 25(6):708–714
Rednam S et al (2013) Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma. Pediatr Blood Cancer 60(4):593–598
Pussegoda K et al (2013) Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther 94(2):243–251
Becker B, Cooper MA (2013) Aminoglycoside antibiotics in the 21st century. ACS Chem Biol 8(1):105–115
Karmody CS, Weinstein L (1977) Reversible sensorineural hearing-loss with intravenous erythromycin lactobionate. Ann Otol Rhinol Laryngol 86(1):9–11
Swanson DJ et al (1992) Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia. Am J Med 92(1):61–68
Kobayashi T et al (1997) Ototoxic effect of erythromycin on cochlear potentials in the guinea pig. Ann Otol Rhinol Laryngol 106(7 Pt 1):599–603
Beaugard ME, Asakuma S, Snow JB Jr (1981) Comparative ototoxicity of chloramphenicol and kanamycin with ethacrynic acid. Arch Otolaryngol 107(2):104–109
Henley CM et al (1984) Impairment in cochlear function produced by chloramphenicol and noise. Neuropharmacology 23(2A):197–202
Gao WY et al (2004) Ototoxicity of a new glycopeptide, norvancomycin with multiple intravenous administrations in guinea pigs. J Antibiot 57(1):45–51
Lutz H et al (1991) Ototoxicity of vancomycin – an experimental-study in Guinea-Pigs. ORL J Otorhinolaryngol Relat Spec 53(5):273–278
Forouzesh A, Moise PA, Sakoulas G (2009) Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 53(2):483–486
Wright CG, Meyerhoff WL, Halama AR (1987) Ototoxicity of neomycin and polymyxin-B following middle-ear application in the Chinchilla and Baboon. Am J Otol 8(6):495–499
Rakover Y, Keywan K, Rosen G (1997) Safety of topical ear drops containing ototoxic antibiotics. J Otolaryngol 26(3):194–196
Knight KR et al (2007) Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 25(10):1190–1195
Frisina RD et al (2016) Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 34(23):2712–2720
Landier W et al (2014) Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales – a report from the Children’s Oncology Group. J Clin Oncol 32(6):527–534
Qaddoumi I et al (2012) Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30(10):1034–1041
Knight KR, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23(34):8588–8596
Landier W (2016) Ototoxicity and cancer therapy. Cancer 122(11):1647–1658
Ding D et al (2002) Ethacrynic acid rapidly and selectively abolishes blood flow in vessels supplying the lateral wall of the cochlea. Hear Res 173(1–2):1–9
Liu H et al (2011) Ototoxic destruction by co-administration of kanamycin and ethacrynic acid in rats. J Zhejiang Univ Sci B 12(10):853–861
Ding D et al (2007) Cell death after co-administration of cisplatin and ethacrynic acid. Hear Res 226(1–2):129–139
Cazals Y (2000) Auditory sensori-neural alterations induced by salicylate. Prog Neurobiol 62(6):583–631
Didier A, Miller JM, Nuttall AL (1993) The vascular component of sodium salicylate ototoxicity in the guinea pig. Hear Res 69(1–2):199–206
Huang ZW et al (2005) Paradoxical enhancement of active cochlear mechanics in long-term administration of salicylate. J Neurophysiol 93(4):2053–2061
Claessen FAP et al (1998) Quinine pharmacokinetics: ototoxic and cardiotoxic effects in healthy Caucasian subjects and in patients with falciparum malaria. Tropical Med Int Health 3(6):482–489
Bortoli R, Santiago M (2007) Chloroquine ototoxicity. Clin Rheumatol 26(11):1809–1810
Johansen PB, Gran JT (1998) Ototoxicity due to hydroxychloroquine: report of two cases. Clin Exp Rheumatol 16(4):472–474
Tange RA et al (1997) Ototoxic reactions of quinine in healthy persons and patients with Plasmodium falciparum infection. Auris Nasus Larynx 24(2):131–136
Jourde-Chiche N et al (2012) Antimalarial ototoxicity: an underdiagnosed complication? a study of spontaneous reports to the French Pharmacovigilance Network. Ann Rheum Dis 71(9):1586–1587
Huth ME et al (2015) Designer aminoglycosides prevent cochlear hair cell loss and hearing loss. J Clin Invest 125(2):583–592
Heinrich UR et al (2015) Cell-specific accumulation patterns of gentamicin in the guinea pig cochlea. Hear Res 326:40–48
Suzuki M, Kaga K (1996) Effect of cisplatin on the negative charge barrier in strial vessels of the Guinea Pig. A transmission electron microscopic study using polyethyleneimine molecules. Eur Arch Otorhinolaryngol 253(6):351–355
Suzuki M et al (2002) Effect of noise exposure on blood-labyrinth barrier in guinea pigs. Hear Res 164(1–2):12–18
Salt AN, Ma Y (2001) Quantification of solute entry into cochlear perilymph through the round window membrane. Hear Res 154(1–2):88–97
Imamura S, Adams JC (2003) Distribution of gentamicin in the guinea pig inner ear after local or systemic application. J Assoc Res Otolaryngol 4(2):176–195
Rosario MC et al (1998) Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol 46(3):229–236
Gyselynck AM, Forrey A, Cutler R (1971) Pharmacokinetics of gentamicin – distribution and plasma and renal clearance. J Infect Dis 124:S70–S76
Posyniak A, Zmudzki J, Niedzielska J (2001) Sample preparation for residue determination of gentamicin and neomycin by liquid chromatography. J Chromatogr A 914(1–2):59–66
Alfthan O, Renkonen OV, Sivonen A (1973) Concentration of gentamicin in serum, urine and urogenital tissue in man. Acta Pathol Microbiol Scand B-Microbiol 81:92–94
Mingeot-Leclercq MP, Tulkens PM (1999) Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 43(5):1003–1012
Deconti RC et al (1973) Clinical and pharmacological studies with Cis-Diamminedichloroplatinum(Ii). Cancer Res 33(6):1310–1315
Pendyala L, Creaven PJ (1993) In-vitro cytotoxicity, protein-binding, red-blood-cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53(24):5970–5976
Jacobs C et al (1980) Renal handling of Cis-Diamminedichloroplatinum(Ii). Cancer Treat Rep 64(12):1223–1226
Graham MA et al (2000) Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 6(4):1205–1218
Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994–1007
Brillet G et al (1994) Long-term renal effect of cisplatin in man. Am J Nephrol 14(2):81–84
Cho W (2006) Building signaling complexes at the membrane. Sci STKE 2006(321):pe7
Lesniak W, Pecoraro VL, Schacht J (2005) Ternary complexes of gentamicin with iron and lipid catalyze formation of reactive oxygen species. Chem Res Toxicol 18(2):357–364
Orrenius S (2007) Reactive oxygen species in mitochondria-mediated cell death. Drug Metab Rev 39(2–3):443–455
Priuska EM, Schacht J (1995) Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem Pharmacol 50(11):1749–1752
Baliga R et al (1998) In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 53(2):394–401
Dehne N et al (2001) Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol 174(1):27–34
Holzer AK et al (2004) The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66(4):817–823
Ohrvik H, Thiele DJ (2015) The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy. J Trace Elem Med Biol 31:178–182
More SS et al (2010) Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci 30(28):9500–9509
Chinnery PF, Hudson G (2013) Mitochondrial genetics. Br Med Bull 106:135–159
Li H et al (2015) Local mechanisms for loud sound-enhanced aminoglycoside entry into outer hair cells. Front Cell Neurosci 9:130
Turrens JF (2003) Mitochondrial formation of reactive oxygen species. J Physiol 552(Pt 2):335–344
Garcia-Berrocal JR et al (2007) The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear. Br J Pharmacol 152(7):1012–1020
Shen HM, Liu ZG (2006) JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 40(6):928–939
Clerici WJ, DiMartino DL, Prasad MR (1995) Direct effects of reactive oxygen species on cochlear outer hair cell shape in vitro. Hear Res 84(1–2):30–40
Forge A, Li L (2000) Apoptotic death of hair cells in mammalian vestibular sensory epithelia. Hear Res 139(1–2):97–115
Mielke K, Herdegen T (2000) JNK and p38 stresskinases – degenerative effectors of signal-transduction-cascades in the nervous system. Prog Neurobiol 61(1):45–60
Rybak LP, Whitworth CA (2005) Ototoxicity: therapeutic opportunities. Drug Discov Today 10(19):1313–1321
Ylikoski J et al (2002) Blockade of c-Jun N-terminal kinase pathway attenuates gentamicin-induced cochlear and vestibular hair cell death. Hear Res 166(1–2):33–43
Nakamagoe M et al (2010) Estradiol protects the cochlea against gentamicin ototoxicity through inhibition of the JNK pathway. Hear Res 261(1–2):67–74
Lee JE et al (2004) Signaling pathway for apoptosis of vestibular hair cells of mice due to aminoglycosides. Acta Otolaryngol 124:69–74
Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281(5381):1305–1308
Watanabe K et al (2003) Expression of caspase-activated deoxyribonuclease (CAD) and caspase 3 (CPP32) in the cochlea of cisplatin (CDDP)-treated guinea pigs. Auris Nasus Larynx 30(3):219–225
Wang J et al (2004) Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res 64(24):9217–9224
Theneshkumar S et al (2009) Effect of noise conditioning on cisplatin-induced ototoxicity: a pilot study. Med Sci Monit 15(7):BR173–BR177
Fetoni AR et al (2012) Antioxidant treatment with coenzyme Q-ter in prevention of gentamycin ototoxicity in an animal model. Acta Otorhinolaryngol Ital 32(2):103–110
Campbell KC et al (2016) D-methionine (D-met) significantly reduces kanamycin-induced ototoxicity in pigmented guinea pigs. Int J Audiol 55(5):273–278
Campbell KC et al (2007) Prevention of noise-and drug-induced hearing loss with D-methionine. Hear Res 226(1–2):92–103
Li G et al (2001) Round window membrane delivery of L-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology 22(2):163–176
Ekborn A et al (2003) Intracochlear administration of thiourea protects against cisplatin-induced outer hair cell loss in the guinea pig. Hear Res 181(1–2):109–115
Tokgoz SA et al (2012) Protective effects of vitamins E, B and C and L-carnitine in the prevention of cisplatin-induced ototoxicity in rats. J Laryngol Otol 126(5):464–469
Yassuda CC et al (2008) The role of hyperbaric oxygen therapy (hot) as an otoprotection agent against cisplatin ototoxicity. Acta Cir Bras 23(Suppl 1):72–76; discussion 76
Cunningham LL et al (2004) Overexpression of Bcl-2 prevents neomycin-induced hair cell death and caspase-9 activation in the adult mouse utricle In vitro. J Neurobiol 60(1):89–100
Pfannenstiel SC et al (2009) Bcl-2 gene therapy prevents aminoglycoside-induced degeneration of auditory and vestibular hair cells. Audiol Neurootol 14(4):254–266
Wang J et al (2003) A peptide inhibitor of c-Jun N-terminal kinase protects against both aminoglycoside and acoustic trauma-induced auditory hair cell death and hearing loss. J Neurosci 23(24):8596–8607
Bowers WJ et al (2002) Neurotrophin-3 transduction attenuates cisplatin spiral ganglion neuron ototoxicity in the cochlea. Mol Ther 6(1):12–18
Li X et al (2011) Protective role of hydrogen sulfide against noise-induced cochlear damage: a chronic intracochlear infusion model. PLoS One 6(10):e26728
Roy S et al (2013) Sound preconditioning therapy inhibits ototoxic hearing loss in mice. J Clin Invest 123(11):4945–4949
McLean WJ et al (2017) Clonal expansion of Lgr5-positive cells from mammalian cochlea and high-purity generation of sensory hair cells. Cell Rep 18(8):1917–1929
Cheng C et al (2017) Characterization of the transcriptomes of Lgr5+ hair cell progenitors and Lgr5– supporting cells in the mouse cochlea. Front Mol Neurosci 10:122
Lu X et al (2017) Bmi1 regulates the proliferation of cochlear supporting cells via the canonical Wnt signaling pathway. Mol Neurobiol 54(2):1326–1339
He Z et al (2017) Autophagy protects auditory hair cells against neomycin-induced damage. Autophagy 13(11):1884–1904
Fang B, Xiao H (2014) Rapamycin alleviates cisplatin-induced ototoxicity in vivo. Biochem Biophys Res Commun 448(4):443–447
Yu H et al (2013) Inhibition of H3K9 methyltransferases G9a/GLP prevents ototoxicity and ongoing hair cell death. Cell Death Dis 4:e506
He Y et al (2015) Inhibition of H3K4me2 demethylation protects auditory hair cells from neomycin-induced apoptosis. Mol Neurobiol 52(1):196–205
Izumikawa M et al (2005) Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. Nat Med 11(3):271–276
Li L et al (2017) Advances in nano-based inner ear delivery systems for the treatment of sensorineural hearing loss. Adv Drug Deliv Rev 108:2–12
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Guo, J., Chai, R., Li, H., Sun, S. (2019). Protection of Hair Cells from Ototoxic Drug-Induced Hearing Loss. In: Li, H., Chai, R. (eds) Hearing Loss: Mechanisms, Prevention and Cure. Advances in Experimental Medicine and Biology, vol 1130. Springer, Singapore. https://doi.org/10.1007/978-981-13-6123-4_2
Download citation
DOI: https://doi.org/10.1007/978-981-13-6123-4_2
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-13-6122-7
Online ISBN: 978-981-13-6123-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)